Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co Dividends per Share Related Terms
Shandong Boan Biotechnology Co Dividends per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co Dividends per Share Chart
FRA:UJ9 vs VRTX, REGN, RVMD: Dividends per Share Comparison
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's Dividend Yield % falls into.
Shandong Boan Biotechnology Co (FRA:UJ9) has a Dividends per Share of €0.00 as of Dec. 2025. Dividends per share represents the per-share amount paid as dividends. View historical data on Shandong Boan Biotechnology Co and its competitors.
Is Shandong Boan Biotechnology Co's Dividends per Share too high?
Shandong Boan Biotechnology Co's current Dividends per Share is €0.00. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Dividends per Share compare to VRTX and REGN?
Shandong Boan Biotechnology Co's Dividends per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Shandong Boan Biotechnology Co and its competitors. Shandong Boan Biotechnology Co's current Dividends per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Dividends per Share of €0.00. The stock's GF Value™ is €1.75, compared to a current price of €0.53 — trading 70% below its estimated fair value. The current Dividends per Share is €0.00. Shandong Boan Biotechnology Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Dividends per Share is €0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.53 is trading 70% below its estimated GF Value™ of €1.75.
Key valuation signals for FRA:UJ9:
Dividends per Share: €0.00
GF Value™: €1.75 vs. price of €0.53 (70% below fair value)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score
Get the complete analysis for FRA:UJ9
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
